Core Viewpoint - The study indicates that the combination of ASC47 and semaglutide significantly enhances weight loss in obese subjects compared to semaglutide alone, with a relative improvement of up to 56.2% [1] Group 1: Drug Efficacy - ASC47, a fat-targeting THRβ agonist, when combined with the gut hormone drug semaglutide, shows a significant synergistic effect on weight loss in obese participants (BMI ≥ 30 kg/m²) [1] - The combination therapy not only improves weight loss outcomes but also significantly enhances gastrointestinal tolerability [1] Group 2: Future Research Implications - The results provide important concept validation data that will inform the design of subsequent Phase IIb combination therapy studies for various metabolic diseases, including obesity and metabolic-associated fatty liver disease (MASH) [1]
歌礼制药-B(01672.HK)宣布ASC47联合司美格鲁肽在肥胖受试者中较司美格鲁肽单药减重效果相对提升高达56.2%